FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2026年2月16日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 ...

Group 1 - The core point of the article is that Dr. Xie Li has resigned as an executive director of Yidu Technology (02158) to focus more on personal matters, effective from February 13, 2026 [1] Group 2 - The announcement indicates a significant leadership change within the company, which may impact its strategic direction and operations [1] - The timing of the resignation suggests potential implications for the company's future initiatives and governance [1] - The company may need to address this leadership transition to maintain investor confidence and operational stability [1]

Group 1 - The core point of the article is that Dr. Xie Li has resigned as an executive director of Yidu Tech (02158) to focus more on personal matters, effective from February 13, 2026 [1] Group 2 - The announcement indicates a significant leadership change within the company, which may impact its strategic direction and operations [1] - The timing of the resignation suggests that the company may need to address succession planning and potential impacts on investor confidence [1] - The company has not provided further details regarding the appointment of a successor or interim leadership arrangements [1]

醫渡科技有限公司（「本公司」）的董事會（「董事會」）成員載列如下，自2026年2月13日起生效。 執行董事 宮盈盈女士 （董事長） 徐濟銘先生 （首席執行官） 封曉瑛女士 非執行董事 Yidu Tech Inc. 醫渡科技有限公司 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 (股份代號：2158) 董事名單及其角色和職能 曾鳴先生 獨立非執行董事 馬維英博士 潘蓉容女士 張林琦教授 董事會設有三個委員會。下表載列該等委員會的成員詳情。 | 董事 | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | | 宮盈盈女士 | | 成員 | 主席 | | 徐濟銘先生 | | | | | 封曉瑛女士 | | | | | 曾鳴先生 | | | | | 馬維英博士 | 成員 | 主席 | 成員 | | 潘蓉容女士 | 主席 | | | | 張林琦教授 | 成員 | 成員 | 成員 | 2026年2月13日 ( ) ...

Group 1 - The core point of the article is that Xie Li has resigned from her position as an executive director of Yidu Tech (02158.HK) to focus more on personal matters, effective from February 13, 2026 [1] Group 2 - The announcement indicates a significant change in the company's leadership structure due to Xie Li's decision [1] - The timing of the resignation may impact the company's strategic direction and operational management in the future [1] - The company may need to address potential concerns from investors regarding leadership stability following this resignation [1]

承董事會命 醫渡科技有限公司 執行董事兼董事長 宮盈盈 醫渡科技有限公司（「本公司」）的董事（「董事」）會（「董事會」）謹此宣佈，謝麗博士（「謝博士」） 因其計劃投入更多時間於其個人事務已辭任執行董事，自2026年2月13日起生效。 謝博士已確認，彼與董事會概無任何意見分歧，亦無任何有關彼辭任的事宜需提請本公司股 東或香港聯合交易所有限公司垂注。 Yidu Tech Inc. 醫渡科技有限公司 ( 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ) (股份代號：2158) 董事會謹藉此機會就謝博士於任期內對本公司作出的寶貴貢獻致以謝意。 執行董事辭任 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲 明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 香港，2026年2月13日 於本公告日期，執行董事為宮盈盈女士、徐濟銘先生及封曉瑛女士；非執行董事為曾鳴先生；及獨立非執行董事為 馬維英博士、潘蓉容女士及張林琦教授。 ...

格隆汇2月12日丨医渡科技(02158.HK)公告，2月12日耗资332.2万港元回购55.8万股。 医渡科技(02158.HK)2月12日耗资332.2万港元回购55.8万股 医渡科技(02158.HK)2月11日耗资290.6万港 元回购48.6万股 相关事件 ...

Group 1 - The core viewpoint of the news highlights that Yidu Tech (02158) has been actively repurchasing its shares, demonstrating confidence in its value and the industry's prospects, with a total repurchase amount exceeding 64 million HKD [1] - On February 11, the State Council emphasized the broad prospects of "Artificial Intelligence +" during a special study session, indicating that it will drive consumption and industrial upgrades, opening new growth spaces across various sectors [1] - The continuous share repurchase by Yidu Tech is seen as a positive response to the industry trend aligned with the core empowerment direction of "Artificial Intelligence + Healthcare" [1] Group 2 - Yidu Tech's recent collaboration with Huazhong University of Science and Technology Tongji Medical College Affiliated Tongji Hospital on a multimodal AI database project for gastrointestinal tumors has been selected for the Ministry of Industry and Information Technology's 2025 AI medical device innovation task list [2] - Being included in the "recruitment list" reflects Yidu Tech's strong capabilities in the AI healthcare field and aligns its business layout with national strategic needs, laying a foundation for the company to seize opportunities in the commercialization wave of AI healthcare [2]

Group 1 - The core viewpoint of the articles highlights the strong confidence of the company in its value and the industry outlook, as evidenced by its continuous share buyback actions totaling over 64 million HKD [1] - The company has repurchased approximately 560,000 shares at around 5.95 HKD per share on February 12, marking the 14th consecutive trading day of intensive buybacks [1] - The recent government meeting emphasized the broad prospects of "Artificial Intelligence+" which is expected to drive consumption and industrial upgrades, providing strong development momentum for the AI healthcare sector [1] Group 2 - The company has successfully entered the "Revealing the List" of the Ministry of Industry and Information Technology's 2025 AI medical device innovation tasks with a multimodal AI database project in collaboration with Tongji Hospital [2] - This inclusion reflects the company's strong capabilities in the AI medical field and aligns its business layout with national strategic needs, positioning it to seize opportunities in the commercialization wave of AI healthcare [2]

Group 1 - The company, Yidu Tech (02158), announced a share buyback of 558,000 shares at a cost of HKD 3.3225 million on February 12, 2026 [1]